Voyager Therapeutics has filed an S-1 form with
the Securities and Exchange Commission (SEC) for its initial public offering
(IPO). Roughly 4.69 million shares are expected, within the range of $15 to
$17, with an overallotment option for an additional 703,125 shares. At the maximum
price, the entire offering is valued up to $91.64 million. The company intends
to list on the Nasdaq Global Market under the symbol VYGR.
The
underwriters for the offering are Cowen, Piper Jaffray, Nomura and Wedbush
PacGrow.
This
clinical-stage gene therapy company is focused on
developing life-changing treatments for patients suffering from severe diseases
of the central nervous system (CNS). The company focuses on CNS diseases where
it believes that an adeno-associated virus (AAV) gene therapy approach that
either increases or decreases the production of a specific protein can slow or
reduce the symptoms experienced by patients and therefore have a clinically
meaningful impact.
The
company has created a product engine that enables it to engineer, optimize,
manufacture and deliver its AAV-based gene therapies that have the potential to
provide durable efficacy following a single administration directly to the CNS.
The product engine has rapidly generated programs for five CNS indications,
including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral
sclerosis, or a form of the disease caused by a single gene mutation;
Friedreich’s ataxia; Huntington’s disease; and spinal muscular atrophy.
Voyager’s
most advanced clinical candidate, VY-AADC01, is being evaluated for the
treatment of advanced Parkinson’s disease in an open-label, Phase 1b clinical
trial with the goal of generating human proof-of-concept data in the second
half of 2016.
The
founders and members of the management team have extensive experience in drug
discovery and development and have pioneered significant advances within the
fields of AAV gene therapy and neuroscience.
Voyager
intends to use the net proceeds from this offering to fund the costs of future
clinical development and to fund the costs of additional preclinical
development, manufacturing and clinical development, including Phase 1 and
later-stage clinical trials. The remainder of the
proceeds will be used to fund working capital and other general corporate
purposes.
http://247wallst.com/healthcare-business/2015/10/30/voyager-therapeutics-sets-terms-for-ipo/
No comments:
Post a Comment